Along with these observations, mice that were engineered to overexpress the β-adrenoreceptor or Gα protein displayed initial sustained increases in heart rate and ventricular contractile function, followed by ventricular dilation, myocardial fibrosis, and heart failure.33 In contrast, there were distinct differences in mice with cardiac-directed expression of AC6—despite 20-fold excess cardiac AC6 protein, there was no increase in heart rate or left ventricular function in unstimulated Inhibitors,research,lifescience,medical animals. Moreover, the animals displayed improved responsiveness to β-adrenoreceptor stimulation by showing marked increases in heart rate and contractile function. Most importantly,
unlike mice with cardiac-directed β-adrenoreceptor or Gα, there was no decline in function or abnormalities of cardiac
Inhibitors,research,lifescience,medical structure or histology even in old mice. The precise mechanisms for these striking differences in effect were not determined. Exogenous gene transfer will be required if AC6 is ever to be applied in the treatment of clinical heart failure, and so far clinical trials are lacking. Istaroxime is a non-cardiac glycoside that has inhibitory effects on the Na+/K+-ATPase pump, and it is check details suggested to possess SERCA-stimulatory abilities.34 The inhibition of the Na+/K+-ATPase pump increases intracellular sodium, Inhibitors,research,lifescience,medical which reduces the driving force for the sodium calcium exchanger (NCX) and decreases calcium extrusion
from the cell. The increased sodium may actually stimulate the NCX to function in the reverse mode and transport calcium into the cell in exchange for sodium. Inhibitors,research,lifescience,medical The calcium influx into the cytosol is expected to increase contractility, but may also be harmful in the failing heart which already has elevated diastolic calcium levels. This mechanism likely explains the modest benefit of drugs such as digoxin in heart Inhibitors,research,lifescience,medical failure. Therefore the additional capability to promote SERCA activity and the uptake of calcium to the sarcoplasmic reticulum may be crucial to the success of an inotropic agent that blocks the Na+/K+-ATPase pump. In several animal studies, istaroxime increased the maximum rates of rise and fall in left ventricular pressure and decreased end-diastolic pressure and volume without a change in heart Montelukast Sodium rate and blood pressure. Most importantly, these inotropic and lusitropic (relaxation) effects were different from those of digoxin and have not been associated with an increase in myocardial oxygen consumption.35 In the HORIZON trial (a randomized, double-blind, placebo-controlled study that recruited 120 patients with relatively mild heart failure that did not require inotropes), an intravenous infusion of istaroxime resulted in an increase in systolic blood pressure and a transient increase in cardiac index, without a change in ejection fraction.